<?xml version="1.0" encoding="UTF-8"?>
<ref id="tca13424-bib-0006">
 <label>6</label>
 <mixed-citation publication-type="journal" id="tca13424-cit-0006">
  <string-name>
   <surname>Zhong</surname>
   <given-names>WZ</given-names>
  </string-name>, 
  <string-name>
   <surname>Wang</surname>
   <given-names>Q</given-names>
  </string-name>, 
  <string-name>
   <surname>Mao</surname>
   <given-names>WM</given-names>
  </string-name>
  <italic>et al</italic>
  <article-title>Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II‐IIIA (N1‐N2) EGFR‐mutant NSCLC (ADJUVANT/CTONG1104): A randomised, open‐label, phase 3 study</article-title>. 
  <source xml:lang="en">Lancet Oncol</source>
  <year>2018</year>; 
  <volume>19</volume>: 
  <fpage>139</fpage>–
  <lpage>48</lpage>.
  <pub-id pub-id-type="pmid">29174310</pub-id>
 </mixed-citation>
</ref>
